Breast tumor subgroups reveal diverse clinical prognostic power

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Liu, Zhaoqi ^a   Zhang, Xiang Sun ^a   Zhang, Shihua ^a  

^a CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ARTICLE; BREAST TUMOR; CLASSIFICATION; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MORTALITY; PROGNOSIS;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84923369732     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04002     Document Type: Article

References (38)

1. van t Veer, L. J. et al.Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002)
2. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 351, 2817-2826 (2004) (Pubitemid 40051905)
3. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000)
4. Srlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 9819, 10869-10874 (2001)
5. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100, 8418-8423 (2003) (Pubitemid 36842560)
6. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27, 1160-1167 (2009)
7. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012)
8. Rouzier, R. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11, 5678-5685 (2005) (Pubitemid 41170290)
9. Rody, A. et al. The erbB21cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast 16, 235-240 (2007) (Pubitemid 46796861)
10. Carey, L. A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502 (2006) (Pubitemid 43854964)
11. Prat, A. et al. Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer. Oncologist 18, 123-133 (2013)
12. Perou, C. M. Molecular stratification of triple-negative breast cancers. Oncologist 16, 61-70 (2011)
13. Rody, A. et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 13, R97 (2011)
14. Hallett, R. M. et al. A gene signature for predicting outcome in patients with basallike breast cancer. Sci Rep 2, 227 (2012)
15. Moestue, S. A. et al. Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. Breast Cancer Res 15, R16 (2013)
16. Cheang, M. C. et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14, 1368-1376 (2008) (Pubitemid 351413917)
17. Kauraniemi, P. et al. Effects of Herceptin treatment on global gene expression patterns in HER2-Amplified and nonamplified breast cancer cell lines. Oncogene 23, 1010-1013 (2003)
18. Paik, S. et al. Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 24, 3726-3734 (2006) (Pubitemid 46622311)
19. Naderi, A. et al. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26, 1507-1516 (2006) (Pubitemid 46340809)
20. Wang, Y. et al. Gene-expression profiles to predict distant metastasis of lymphnode- negative primary breast cancer. Lancet 365, 671-679 (2005) (Pubitemid 40260888)
21. Venet, D., Dumont, J. E. & Detours, V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Computat Biol 7, e1002240 (2011)
22. Wu, G. & Stein, L. A network module-based method for identifying cancer prognostic signatures. Genome Biol 13, R112 (2012)
23. Margolin, A. A. et al. Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med 5, 181re1-181re1 (2013)
24. Katayama, H. et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 36, 55-62 (2003) (Pubitemid 38056208)
25. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell. 144, 646-674 (2011)
26. Bischoff, J. R. et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17, 3052-3065 (1998) (Pubitemid 28254378)
27. Walter, A. O., Seghezzi, W., Korver, W., Sheung, J. & Lees, E. The mitotic serine/ threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene 19, 4906-4916 (2000)
28. Wheatley, S. P., Carvalho, A., Vagnarelli, P. & Earnshaw, W. C. INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol. 11, 886-890 (2001) (Pubitemid 32532816)
29. Zeitlin, S. G., Shelby, R. D. & Sullivan, K. F. CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis. J Cell Biol. 155, 1147-1158 (2001)
30. De Lange, T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 19, 2100-2110 (2005) (Pubitemid 41330312)
31. Cheng, W. Y., Ou Yang, T. H. & Anastassiou, D. Development of a prognostic model for breast cancer survival in an open challenge environment. Sci Transl Med 5, 181ra50-181ra50 (2013)
32. Cheng, W. Y., Ou Yang, T. H. & Anastassiou, D. Biomolecular events in cancer revealed by attractor metagenes. PLoS Computat Biol 9(2), e1002920 (2013)
33. Fredlund, E. et al. The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Res. 14, R113 (2012)
34. Peddi, P. F., Ellis, M. J. & Ma, C. Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2012, 217185 (2012)
35. Herschkowitz, J. I. et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8, R76 (2007)
36. Bair, E. & Tibshirani, R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2, e108 (2004)
37. Steck, H., Krishnapuram, B., Dehing-oberije, C., Lambin, P. & Raykar, V. C. On ranking in survival analysis: Bounds on the concordance index. In Advances in Neural Information Processing Systems 2007. pp. 1209-1216.
38. Wu, G., Feng, X. & Stein, L. A human functional protein interaction network and its application to cancer data analysis. Genome Biol 11, R53 (2010) of China